Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.47 |
| ▸ | IDH2 | P48735 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 6/20 | 0.43 |
| ▸ | BRAF | P15056 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.36 |
| ▸ | KIT | P10721 | 3/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | CSF1R | P07333 | 2/20 | 0.36 |
| ▸ | LYN | P07948 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | FLT1 | P17948 | 2/20 | 0.36 |
| ▸ | FLT4 | P35916 | 2/20 | 0.36 |
| ▸ | BLK | P51451 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260680 | 0.91 | KDR (0.52) | NTRK1IDH2KDRBRAFRIPK1 | |
| SCHEMBL4256796 | 0.89 | ALDH1A1 (0.44) | NTRK1KDRBRAF | |
| SCHEMBL4260696 | 0.88 | NTRK1 (0.49) | NTRK1IDH2KDRRIPK1KIT | |
| SCHEMBL4259140 | 0.87 | ALDH1A1 (0.49) | NTRK1IDH2KDRBRAFRIPK1 | |
| SCHEMBL4259437 | 0.87 | KDR (0.41) | NTRK1IDH2KDRBRAFRIPK1 | |
| SCHEMBL2337959 | 0.86 | NTRK1 (0.51) | NTRK1IDH2KDRRIPK1KIT | |
| SCHEMBL4259334 | 0.79 | IDH2 (0.50) | NTRK1IDH2KDRRIPK1KIT | |
| SCHEMBL4259330 | 0.79 | KDR (0.52) | NTRK1IDH2KDRRIPK1KIT | |
| SCHEMBL4259427 | 0.77 | ALDH1A1 (0.44) | NTRK1KDRRIPK1KITFLT3 | |
| SCHEMBL2333899 | 0.77 | NTRK1 (0.51) | NTRK1KDRRIPK1KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | claimed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | claimed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | claimed |
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GESELLSCHAFT (DE) | 2009-05-14 | — | — | US | disclosed |
| EP-2004631-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | Merck Patent GmbH (DE) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007115670-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | MERCK PATENT GMBH (DE) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124633-A1 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES | ABL1, NME2, MAP3K1 | NTRK1 828/4885IDH2 481/4885KDR 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.